MD20130089A2 - Metodă de tratament al mielomului multiplu - Google Patents

Metodă de tratament al mielomului multiplu

Info

Publication number
MD20130089A2
MD20130089A2 MDA20130089A MD20130089A MD20130089A2 MD 20130089 A2 MD20130089 A2 MD 20130089A2 MD A20130089 A MDA20130089 A MD A20130089A MD 20130089 A MD20130089 A MD 20130089A MD 20130089 A2 MD20130089 A2 MD 20130089A2
Authority
MD
Moldova
Prior art keywords
multiple myeloma
myeloma treatment
treatment
prevalence
phenotype
Prior art date
Application number
MDA20130089A
Other languages
English (en)
Russian (ru)
Inventor
Кристофер Джон Бернс
Эндрю Спенсер
Кэтрин Энн МОНАГАН
Original Assignee
Ym Biosciences Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47107683&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20130089(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ym Biosciences Australia Pty Ltd filed Critical Ym Biosciences Australia Pty Ltd
Publication of MD20130089A2 publication Critical patent/MD20130089A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Metodă de tratament al mielomului multiplu la etapa creșterii prevalenței celulelor MM (1), care sunt neresponsive la IL-6 și/sau posedă un fenotip CD45 (2), include administrarea unei cantități de compus cu formula Ib:
MDA20130089A 2011-05-02 2012-05-01 Metodă de tratament al mielomului multiplu MD20130089A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481425P 2011-05-02 2011-05-02
PCT/AU2012/000462 WO2012149602A1 (en) 2011-05-02 2012-05-01 Multiple myeloma treatment

Publications (1)

Publication Number Publication Date
MD20130089A2 true MD20130089A2 (ro) 2014-05-31

Family

ID=47107683

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20130089A MD20130089A2 (ro) 2011-05-02 2012-05-01 Metodă de tratament al mielomului multiplu

Country Status (20)

Country Link
US (1) US20140171433A1 (ro)
EP (1) EP2704722A4 (ro)
JP (1) JP2014514337A (ro)
KR (1) KR20140081757A (ro)
CN (1) CN103533939A (ro)
AP (1) AP2013007281A0 (ro)
AU (1) AU2012250491A1 (ro)
BR (1) BR112013028420A2 (ro)
CA (1) CA2834414A1 (ro)
CL (1) CL2013003143A1 (ro)
CO (1) CO6900134A2 (ro)
EA (1) EA201391591A1 (ro)
IL (1) IL228981A0 (ro)
MA (1) MA35129B1 (ro)
MD (1) MD20130089A2 (ro)
MX (1) MX2013012785A (ro)
PE (1) PE20140750A1 (ro)
SG (1) SG194212A1 (ro)
WO (1) WO2012149602A1 (ro)
ZA (1) ZA201308918B (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702650C (en) 2007-03-12 2017-01-03 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
ES2946179T3 (es) 2014-05-28 2023-07-13 Onco Tracker Inc Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CA2955788C (en) 2014-07-22 2024-01-16 Ziyong Sun Anti-pd-1 antibodies
CN110964109B (zh) 2014-08-05 2023-08-25 中美冠科生物技术（太仓）有限公司 抗pd-l1抗体
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 ***啉苯基氨基嘧啶化合物或其盐的多晶型物
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
CN106075046A (zh) * 2016-07-31 2016-11-09 孙书芳 一种治疗肝肾阴虚型多发性骨髓瘤的中药
US10487321B2 (en) * 2016-09-29 2019-11-26 PZM Diagnostics, LLC Method of extraction of genomic DNA for molecular diagnostics and application
WO2019055930A1 (en) * 2017-09-15 2019-03-21 University Of Iowa Research Foundation METHODS OF IDENTIFYING MYELOMA TUMOR INITIATOR CELLS AND TARGETED THERAPY
CN109045040A (zh) * 2018-03-12 2018-12-21 首都医科大学附属北京天坛医院 Cyt387用于制备治疗神经胶质瘤的药物的应用
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536222A (ja) * 2004-05-05 2007-12-13 セルジーン・コーポレーション 癌及び他の疾患を治療及び管理するための選択的サイトカイン阻害薬を用いた方法及び組成物
WO2008064866A1 (en) * 2006-11-27 2008-06-05 Ares Trading S.A. Treatment for multiple myeloma
CA2702650C (en) * 2007-03-12 2017-01-03 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof

Also Published As

Publication number Publication date
AU2012250491A1 (en) 2013-05-02
IL228981A0 (en) 2013-12-31
EA201391591A1 (ru) 2014-12-30
SG194212A1 (en) 2013-11-29
ZA201308918B (en) 2014-08-27
MA35129B1 (fr) 2014-05-02
CO6900134A2 (es) 2014-03-20
CN103533939A (zh) 2014-01-22
CL2013003143A1 (es) 2014-07-04
MX2013012785A (es) 2014-05-28
EP2704722A1 (en) 2014-03-12
US20140171433A1 (en) 2014-06-19
WO2012149602A1 (en) 2012-11-08
BR112013028420A2 (pt) 2017-01-24
AP2013007281A0 (en) 2013-11-30
JP2014514337A (ja) 2014-06-19
KR20140081757A (ko) 2014-07-01
PE20140750A1 (es) 2014-07-06
EP2704722A4 (en) 2014-11-05
CA2834414A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
MD20130089A2 (ro) Metodă de tratament al mielomului multiplu
MY183661A (en) Treatment of cancer with tor kinase inhibitors
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
PH12015500719A1 (en) Gdf-8-inhibitors
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
MY162933A (en) Chemical compounds
MX352975B (es) Piridina y derivados de pirazina.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX345127B (es) Derivados de tiazol.
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
IN2014CN04634A (ro)
PH12014500990A1 (en) Methods for treating gout flares
MX2014003223A (es) Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf.
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2016002308A (es) Tratamiento del mieloma multiple.
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.
EA201490725A1 (ru) Способ лечения мукоэпидермоидной карциномы
MX2014006255A (es) Tratamientos neurologiocos con metaloporfirina.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
MX2013006066A (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.

Legal Events

Date Code Title Description
HK9A Erratum in official gazette with regard to application (patent for invention)

Free format text: CHANGE INVENTOR NAMD: "BURNS CRISTOPHER JOHN" TO "BURNS CHRISTOPHER JOHN"

FA9A Abandonment or withdrawal of application (patent for invention)